Idiopathic pulmonary fibrosis (IPF) is a rare, sporadic, and fatal interstitial lung disease. As the morbidity and mortality rates associated with IPF remain high, prompt idiopathic pulmonary fibrosis treatment is critical to safeguard individuals\u2019 lung function, reduce the risk of acute exacerbations, and improve outcomes.<\/p>\n\n\n\n
According to the National Institutes of Health (NIH), idiopathic pulmonary fibrosis affects approximately 100,000<\/strong> people in the United States. Every year, between 30,000 and 40,000<\/strong> new cases are diagnosed. Idiopathic pulmonary fibrosis affects 13 to 20 people<\/strong> out of every 100,000<\/strong> people worldwide<\/p>\n\n\n\n As per DelveInsight\u2019s latest published Idiopathic Pulmonary Fibrosis Epidemiology Forecast Report<\/a>, the total diagnosed prevalent cases of idiopathic pulmonary fibrosis in the 7MM was 194K cases in 2021, which is expected to rise at a CAGR of 1.1% during the study period (2019\u20132032).<\/strong><\/p><\/blockquote>\n\n\n\n